Familial Adenomatous Polyposis (Genitourinary Disorders) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis (Genitourinary Disorders) – Drugs In Development, 2021, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.

Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason and abdominal pain. Treatment includes surgery and medications (NSAIDs).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Familial Adenomatous Polyposis (Genitourinary Disorders) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 1, 4, 8, 1 and 1 respectively.

Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).

– The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

ADT Pharmaceuticals Inc

Cancer Prevention Pharmaceuticals Inc

Cellix Bio Pvt Ltd

DNAlite Therapeutics Inc

Eloxx Pharmaceuticals Inc

Emtora Biosciences

FunPep Co Ltd

GLW Pharma

Johnson & Johnson

Recursion Pharmaceuticals Inc

SanaRx Biotherapeutics Inc

Stemsynergy Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

TherapyX Inc

Thetis Pharmaceuticals LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Familial Adenomatous Polyposis - Overview

Familial Adenomatous Polyposis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Familial Adenomatous Polyposis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development

ADT Pharmaceuticals Inc

Cancer Prevention Pharmaceuticals Inc

Cellix Bio Pvt Ltd

DNAlite Therapeutics Inc

Eloxx Pharmaceuticals Inc

Emtora Biosciences

FunPep Co Ltd

GLW Pharma

Johnson & Johnson

Recursion Pharmaceuticals Inc

SanaRx Biotherapeutics Inc

Stemsynergy Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

TherapyX Inc

Thetis Pharmaceuticals LLC

Familial Adenomatous Polyposis - Drug Profiles

(eflornithine hydrochloride + sulindac) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLXONC-57 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FAPXIL SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Familial Adenomatous Polyposis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guselkumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icosapent ethyl - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interleukin-10 SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

magnesium lysinate bis eicosapentaenoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ombipepimut-s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrvinium pamoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REC-4881 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Colorectal Cancer and Familial Adenomatous Polyposis (FAP) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Familial Adenomatous Polyposis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PDE10 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic peptide for Familial Adenomatous Polyposis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Familial Adenomatous Polyposis - Dormant Projects

Familial Adenomatous Polyposis - Discontinued Products

Familial Adenomatous Polyposis - Product Development Milestones

Featured News & Press Releases

Sep 11, 2020: Cancer Prevention Pharmaceuticals Announces NEJM publication of landmark phase 3 clinical trial for treatment of familial adenomatous polyposis

Jun 29, 2020: Cancer Prevention Pharmaceuticals submits New Drug Application to the FDA for CPP-1X/sul for treatment of familial adenomatous polyposis

Jun 18, 2020: Cancer Prevention Pharmaceuticals submits EU marketing authorization application for CPP-1X/sul for treatment of familial adenomatous polyposis

Apr 15, 2020: KD Pharma and SLA Pharma to study EPAspire for Covid-19

Nov 17, 2019: National Institute of Diabetes and Digestive and Kidney Diseases awards $2,073,687 SBIR fasttrack grant to Therapyx

Aug 26, 2019: Emtora Biosciences awarded $3 million CPRIT grant to study efficacy of eRapa in familial adenomatous polyposis

Aug 01, 2019: SLA Pharma announces meeting with the FDA in October 2019 for ALFA

Jun 20, 2019: Cancer Prevention Pharmaceuticals (CPP) reports FAP phase 3 clinical trial results at Digestive Disease Week Conference

May 07, 2019: Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt announce results from pivotal phase 3 trial of CPP-1X/Sulindac in patients with familial adenomatous polyposis

Apr 15, 2019: MorphoSys announces that its licensee Janssen has expanded clinical development of Guselkumab (Tremfya) into familial adenomatous polyposis

Feb 26, 2019: Rapamycin Holdings rebrands to Emtora Biosciences as new leadership focuses company on next steps

Dec 10, 2018: Cancer Prevention Pharmaceuticals Announces Last Patient Completes Phase 3 Trial Protocol of CPP-1X/sul for Familial Adenomatous Polyposis

Nov 19, 2018: Cancer Prevention Pharmaceuticals to present at Piper Jaffray Healthcare Conference in NYC, November 28, 2018

Oct 22, 2018: Marc L. Tokars Joins Cancer Prevention Pharmaceuticals as Vice President of Clinical and Regulatory Affairs

Feb 22, 2018: Cancer Prevention Pharmaceuticals Appoints Willene Brondum Associate Vice President of Regulatory Affairs and Quality Assurance

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Familial Adenomatous Polyposis, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Familial Adenomatous Polyposis – Pipeline by ADT Pharmaceuticals Inc, 2021

Familial Adenomatous Polyposis – Pipeline by Cancer Prevention Pharmaceuticals Inc, 2021

Familial Adenomatous Polyposis – Pipeline by Cellix Bio Pvt Ltd, 2021

Familial Adenomatous Polyposis – Pipeline by DNAlite Therapeutics Inc, 2021

Familial Adenomatous Polyposis – Pipeline by Eloxx Pharmaceuticals Inc, 2021

Familial Adenomatous Polyposis – Pipeline by Emtora Biosciences, 2021

Familial Adenomatous Polyposis – Pipeline by FunPep Co Ltd, 2021

Familial Adenomatous Polyposis – Pipeline by GLW Pharma, 2021

Familial Adenomatous Polyposis – Pipeline by Johnson & Johnson, 2021

Familial Adenomatous Polyposis – Pipeline by Recursion Pharmaceuticals Inc, 2021

Familial Adenomatous Polyposis – Pipeline by SanaRx Biotherapeutics Inc, 2021

Familial Adenomatous Polyposis – Pipeline by Stemsynergy Therapeutics Inc, 2021

Familial Adenomatous Polyposis – Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021

Familial Adenomatous Polyposis – Pipeline by TherapyX Inc, 2021

Familial Adenomatous Polyposis – Pipeline by Thetis Pharmaceuticals LLC, 2021

Familial Adenomatous Polyposis – Dormant Projects, 2021

Familial Adenomatous Polyposis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Familial Adenomatous Polyposis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports